A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada

Feng Xie, Eleanor Pullenayegum, Kathy Gaebel, Nick Bansback, Stirling Bryan, Arto Ohinmaa, Lise Poissant, Jeffrey A Johnson, Canadian EQ-5D-5L Valuation Study Group, F Xie, J A Johnson, N Bansback, S Bryan, L Poissant, E Pullenayegum, Kathy Gaebel, Samantha Pollard, Lidia Engel, Serena Humphries, Fatima Al Sayah, Touria Addou, Feng Xie, Eleanor Pullenayegum, Kathy Gaebel, Nick Bansback, Stirling Bryan, Arto Ohinmaa, Lise Poissant, Jeffrey A Johnson, Canadian EQ-5D-5L Valuation Study Group, F Xie, J A Johnson, N Bansback, S Bryan, L Poissant, E Pullenayegum, Kathy Gaebel, Samantha Pollard, Lidia Engel, Serena Humphries, Fatima Al Sayah, Touria Addou

Abstract

Background: The 5-level version of the EQ-5D (EQ-5D-5L) was recently developed. A number of preference-based scoring systems are being developed for several countries around the world.

Objective: To develop a value set for the EQ-5D-5L based on societal preferences in Canada.

Methods: We used age, sex, and education quota sampling from the general population from 4 cities across Canada. Composite time trade-off (cTTO) and traditional time trade-off (tTTO) were used as the main elicitation technique. A total of 86 EQ-5D-5L health states grouped into 10 blocks were valued using cTTO, whereas a subset of 18 severe states was also valued using tTTO. Participants meeting predefined inconsistency criteria were excluded from the analyses. For the value set development, we used tTTO and positive cTTO values, while censoring negative and zero cTTO values at zero. Models with the main effects presented using linear terms combined with various additional terms were estimated. The preferred model was selected based primarily on logically ordered coefficients, and secondly model fit.

Results: Of the 1209 participants who completed the interview, 136 met criteria that excluded them from the primary analyses. The demographics and socioeconomic status of the remaining 1073 participants were similar to the Canadian general population. The preferred model has 5 linear terms for the main effects, a term for level 4 or 5 for each dimension, and a term for the squared total number of level 4 or 5 beyond the first. For this preferred model, the health utilities ranged from -0.148 for the worst (55555) to 0.949 for the best (11111) EQ-5D-5L states.

Conclusions: This is the first TTO-based value set of the EQ-5D-5L for Canada. It can be used to support the health utility estimation in economic evaluations for reimbursement decision making in Canada.

Conflict of interest statement

F.X. and E.P. are supported by Canadian Institutes of Health Research New Investigator Awards (2012–2017). J.A.J. is a Senior Health Scholar with Alberta Innovates Health Solutions. The remaining authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Distribution of observed tTTO and cTTO values for the 86 health states. Red circle represents observed cTTO score, whereas green circle represents observed tTTO score. The size of the circle corresponds to the frequency of the observed score. cTTO indicates composite TTO; tTTO, traditional TTO; TTO, time trade-off.
FIGURE 2
FIGURE 2
Predicted utilities versus observed utilities for the 86 health states. The green reference line represents perfect prediction for observation. cTTO indicates composite TTO; MAE, mean absolute error; tTTO, traditional TTO; TTO, time trade-off.
FIGURE 3
FIGURE 3
Sensitivity analyses on the inclusion criteria and censoring. Blue line: “the preferred model” that includes participants meeting the inclusion criteria and censoring nonpositive cTTO values at zero. Green line: including all participants and censoring nonpositive cTTO values at zero. Brown line: including participants meeting the inclusion criteria and censoring only negative cTTO values at zero. Purple line: including all participants and censoring only negative cTTO values at zero. cTTO indicates composite time trade-off.

References

    1. Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA). Guidelines for Economic Evaluation of Pharmaceuticals. Ottawa, Canada: CCOHTA; 1997.
    1. Ontario Ministry of Health and Long-Term Care. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Ontario: Ministry of Health; 1994.
    1. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd ed Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
    1. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
    1. Brauer CA, Rosen AB, Greenberg D, et al. Trends in the measurement of health utilities in published cost-utility analyses. Value Health. 2006;9:213–218.
    1. Prosser L, WIttenberg E. Trends in utility elicitation methods: Is there still a role for direct elicitation? In: 32nd Annual Meeting of Society for Medical Decision Making, Toronto, 2010.
    1. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–1736.
    1. Bansback N, Tsuchiya A, Brazier J, et al. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One. 2012;7:e31115.
    1. Oppe M, Devlin NJ, van HB, et al. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17:445–453.
    1. Janssen BM, Oppe M, Versteegh MM, et al. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14(suppl 1):S5–13.
    1. Devlin N, Shah KK, Mulhern B, et al. An EQ-5D-5L value set for England. The EuroQol Group 30th Plenary Meeting. September 12, 2013.
    1. Ramos-Goni J, Pinto-Prades J, Cabases JM, et al. Spanish EQ-5D-5L Valuation project: dealing with inconsistencies of C-TTO responses. The EuroQol Group 30th Plenary Meeting. September 12, 2013.
    1. Versteegh M, Krabbe P, Evers S, et al. A Dutch tariff for the EQ-5D-5L. The EuroQol Group 30th Plenary Meeting. September 12, 2013.
    1. Xie F, Pullenayegum E, Bansback N, et al. The Canadian EQ-5D-5L Valuation Study: An Exploratory Analysis. The EuroQol Group 30th Plenary Meeting. September 12, 2013.
    1. Al Sayah F, Mladenovic A, Gaebel K, et al. How Dead Is Dead? Findings From Interviewing Participants From the Canadian EQVT Valuation Test Retest Study. The EuroQol Group 31th Plenary Meeting. September 25, 2014.
    1. Xie F, Pullenayegum E, Gaebel K, et al. Was composite TTO a worse-than-dead proposition? The EuroQol Group Plenary Meeting. 2014.
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108.
    1. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203–220.

Source: PubMed

3
Subscribe